Drug intelligence / Profile preview

Weikang Granule

Development stage: Preclinical
Lead developer: Southern Medical University
Administration: Oral

Overview

Weikang Granule is a Traditional Chinese Medicine (TCM) preparation in granule form. It is currently being investigated for its potential to regulate gut microbiota in individuals experiencing suboptimal health status. As a multi-component TCM, it is composed of various natural ingredients. Related formulations, such as Wei-Wei-Kang-Granule, have also been studied for conditions like chronic atrophic gastritis, where they have demonstrated effects on pathways including Epidermal growth factor receptor (EGFR) and Nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB).

Other names: 维康颗粒Wei-Wei-Kang-GranuleWeikang Keli

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)NF-κB

Beyond the preview

Go deeper on Weikang Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weikang Granule.

Explore the full profile